ReviewClinical microbiology reviews2022
Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.
Review in Clinical microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- CXCL9/CXCL10 as biomarkers the monitoring of treatment responses in Pulmonary TB patients: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Metagenomic next-generation sequencing forFrontiers in public health · 2023Pooled it
- A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.The Journal of antimicrobial chemotherapy · 2024Trial
- Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid.Antimicrobial agents and chemotherapy · 2024Trial
- Evaluating the nationwide availability of essential diagnostics for tuberculosis toward achieving a TB-free India.Microbiology spectrum · 2026Article
- What is new in tuberculosis?Clinical medicine (London, England) · 2026Review
- Closing gaps through innovation in the tuberculosis pathology value chain.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical Management.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Hospitalization and diabetes mellitus as predictors of unfavorable tuberculosis treatment outcomes.BMC infectious diseases · 2026Article
- Host response biomarkers of tuberculosis recurrence and treatment failure.Communications medicine · 2026Article
- Systemic Host Proteomic Signatures as Dynamic Markers for Monitoring Pulmonary Tuberculosis Treatment Response.Infection and drug resistance · 2026Review
- PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy.Frontiers in immunology · 2026Article
- Beyond culturability: VBNC-like and differentially culturableFrontiers in cellular and infection microbiology · 2026Review
- Clinical evaluation of the diagnostic performances and treatment monitoring of the new PATHFAST TB LAM Ag assay in sputum specimens of patients with tuberculosis or with nontuberculous mycobacteria pulmonary disease.Journal of clinical microbiology · 2025Article
- Clinical standards for antimicrobial stewardship in TB care.IJTLD open · 2025Article
- Accuracy of Machine Learning in Identifying Drug Resistance in Tuberculosis: A Systematic Review and Meta-Analysis.Health science reports · 2025Review
- In Vitro Antimicrobial Activity of Contezolid AgainstMicroorganisms · 2025Article
- Stool-Based Molecular Tuberculosis Treatment Monitoring: A Faster Means for Detecting Persistent Mycobacteria Compared to Phenotypic Culture.Open forum infectious diseases · 2025Article
- Evaluation of the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis in Nairobi, Kenya.Tropical medicine and health · 2025Article
- Reliable, accessible, cost-effective, & easy (RACE) diagnostic modality: A key for elimination of tuberculosis.The Indian journal of medical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.